ABLX / Ablynx NV - SEC फाइलिंग, वार्षिक रिपोर्ट, प्रॉक्सी स्टेटमेंट

ABYLY / Ablynx NV 15-12B

15-12B 1 d583880d1512b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38259 ABLYNX NV (Exact name of registr

Sanofi completes its acquisition of Ablynx following the expiration of the

EX-99.(A)(1)(Q) 2 d612789dex99a1q.htm EXHIBIT (A)(1)(Q) Exhibit (a)(1)(Q) Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure Paris, France and Ghent, Belgium – June 19, 2018 – Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx announced today that Sanofi has now acquired all outstanding shares (including shares represented by American Depositary Shares (“ADS

SNY / Sanofi SC TO-T/A

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 5) Ablynx NV (Name of Subject Company (Issuer)) SANOFI (Names of Filing Persons — Offeror) Ordinary Shares, no nominal value American Depositary Shares, each of which represents one Ordinary Sha

ABYLY / Ablynx NV / Sanofi - AMENDMENT NO.1 TO SCHEDULE 13D Activist Investment

SC 13D/A 1 d612043dsc13da.htm AMENDMENT NO.1 TO SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Ablynx NV (Name of Issuer) Ordinary Shares, no nominal value American Depositary Shares, each representing one Ordinary Share (Title of Class of Securities) ISIN BE0003877942 (Ordinary Shares)

SNY / Sanofi SC TO-T/A

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 4) Ablynx NV (Name of Subject Company (Issuer)) SANOFI (Names of Filing Persons — Offeror) Ordinary Shares, no nominal value American Depositary Shares, each of which represents one Ordinary Sha

ABYLY / Ablynx NV / Sanofi - SCHEDULE 13D Activist Investment

SC 13D 1 d595886dsc13d.htm SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 Ablynx NV (Name of Issuer) Ordinary Shares, no nominal value American Depositary Shares, each representing one Ordinary Share (Title of Class of Securities) ISIN BE0003877942 (Ordinary Shares) CUSIP 00372Y105 (American Depositary Sh

SNY / Sanofi SC TO-T/A

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 3) Ablynx NV (Name of Subject Company (Issuer)) SANOFI (Names of Filing Persons — Offeror) Ordinary Shares, no nominal value American Depositary Shares, each of which represents one Ordinary Sha

ABYLY / Ablynx NV SC 14D9/A

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 2 Ablynx NV (Name of Subject Company) Ablynx NV (Name of Person(s) Filing Statement) Ordinary Shares, no nominal value American Depositary Shares, each representing one Ordinary Share (Title of Clas

Source: Sanofi (EURONEXT: SAN) (NYSE: SNY)

EX-(a)(1)(O) Exhibit (a)(1)(O) Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period Paris, France and Ghent, Belgium – May 14, 2018 – Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx (Euronext Brussels and Nasdaq: ABLX) today announced the results of the initial tender offer period of Sanofi’s previously announced tender offers to acquire all of the outstanding shares (including shares represented by American Depositary Shares (“ADSs”)), warrants and convertible bonds (together, the “Securities”) of Ablynx.

Results of the Initial Acceptance Period of the U.S. Offer to Purchase All Outstanding Ordinary Shares, No Nominal Value, Held By U.S. Holders and All Outstanding Ordinary Shares Represented By Outstanding American Depositary Shares, Held by All Hold

EX-99.(A)(1)(P) 3 d586966dex99a1p.htm EX-(A)(1)(P) Exhibit (a)(1)(P) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares and/or ADSs (both, as defined below). The U.S. Offer (as defined below) is made only by the Offer to Purchase, dated April 4, 2018, the related Share Acceptance Form, the related ADS Letter of Transmittal and the related Share Withdraw

SNY / Sanofi SC TO-T/A

SC TO-T/A 1 d586966dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) Ablynx NV (Name of Subject Company (Issuer)) SANOFI (Names of Filing Persons — Offeror) Ordinary Shares, no nominal value American Depositary Shares, each of wh

ABYLY / Ablynx NV SC 14D9/A

SC 14D9/A 1 d563474dsc14d9a.htm SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 1 Ablynx NV (Name of Subject Company) Ablynx NV (Name of Person(s) Filing Statement) Ordinary Shares, no nominal value American Depositary Shares, each repr

SNY / Sanofi SC TO-T/A

SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) Ablynx NV (Name of Subject Company (Issuer)) SANOFI (Names of Filing Persons — Offeror) Ordinary Shares, no nominal value American Depositary Shares, each of which represents one Ordinary Sha

ABYLY / Ablynx NV 20-F/A

20-F/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A Amendment No. 1 (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15

ABYLY / Ablynx NV SCHEDULE 14D9

SC 14D9 1 d535295dsc14d9.htm SCHEDULE 14D9 Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Ablynx NV (Name of Subject Company) Ablynx NV (Name of Person(s) Filing Statement) Ordinary Shares, no nominal value American Depositary Shares, each r

U.S. Offer to Purchase For Cash ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS AND ALL SHARES REPRESENTED BY OUTSTANDING AMERICAN DEPOSITARY SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED, ABLYNX NV €45.00 PER SHARE, NET TO TH

Exhibit (a)(1)(F) Exhibit (a)(1)(F) U.S. Offer to Purchase For Cash ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS AND ALL SHARES REPRESENTED BY OUTSTANDING AMERICAN DEPOSITARY SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED, of ABLYNX NV at €45.00 PER SHARE, NET TO THE SELLER IN CASH, WITHOUT INTEREST and €45.00 PER AMERICAN DEPOSITARY SHARE, NET TO THE SELLER IN CASH, WITH

U.S. Offer To Purchase For Cash ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS AND ALL SHARES REPRESENTED BY OUTSTANDING AMERICAN DEPOSITARY SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED, ABLYNX NV €45.00 PER SHARE, NET TO TH

Exhibit (a)(1)(A) Table of Contents Exhibit (a)(1)(A) U.S. Offer To Purchase For Cash ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS AND ALL SHARES REPRESENTED BY OUTSTANDING AMERICAN DEPOSITARY SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED, of ABLYNX NV for €45.00 PER SHARE, NET TO THE SELLER IN CASH, WITHOUT INTEREST and €45.00 PER AMERICAN DEPOSITARY SHARE, NET TO THE S

SHARE WITHDRAWAL FORM SHARE WITHDRAWAL FORM FOR THE U.S. OFFER TO PURCHASE FOR CASH ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS OF ABLYNX NV FOR €45.00 PER SHARE, NET TO THE SELLER IN CASH, WITHOUT INTEREST BY SANOFI TO BE

EX-99.A1D 5 d525290dex99a1d.htm EXHIBIT (A)(1)(D) Exhibit (a)(1)(D) SHARE WITHDRAWAL FORM SHARE WITHDRAWAL FORM FOR THE U.S. OFFER TO PURCHASE FOR CASH ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS OF ABLYNX NV FOR €45.00 PER SHARE, NET TO THE SELLER IN CASH, WITHOUT INTEREST BY SANOFI TO BE COMPLETED AND SUBMITTED IN DUPLICATE TO THE FINANCIAL INTERMEDIARY TO WHICH THE S

HEADS OF AGREEMENT RELATING TO A FRIENDLY TENDER OFFER FOR ABLYNX NV

Exhibit (d)(1) Exhibit (d)(1) HEADS OF AGREEMENT RELATING TO A FRIENDLY TENDER OFFER FOR ABLYNX NV These Heads of Agreement (together with their Schedules, this “Agreement”) are executed on January 28, 2018.

AMENDMENT AGREEMENT AND WAIVER Dated 29 March 2018 BNP Paribas Fortis SA/NV acting as Arranger, Lender and Facility Agent RELATING TO A €4,200,000,000 TERM FACILITY AGREEMENT DATED 28 January 2018

Exhibit (b)(2) Exhibit(b)(2) AMENDMENT AGREEMENT AND WAIVER Dated 29 March 2018 SANOFI and BNP Paribas Fortis SA/NV acting as Arranger, Lender and Facility Agent RELATING TO A €4,200,000,000 TERM FACILITY AGREEMENT DATED 28 January 2018 THIS AGREEMENT is dated 29 March 2018 and made between: (1) SANOFI, a French société anonyme whose registered office at 54, rue La Boétie, 75008 Paris, France, registered under identification number 395 030 844 RCS Paris as original borrower (the “Company”); (2) BNP PARIBAS FORTIS SA/NV, having its registered office at Montagne du Parc 3, B-1000 Brussels as Arranger and Lender; and (3) BNP PARIBAS FORTIS SA/NV as Facility Agent.

Notice of Offer to Purchase All Outstanding Ordinary Shares, No Nominal Value, Held By U.S. Holders and All Shares Represented By Outstanding American Depositary Shares, Held by All Holders, Wherever Located, of ABLYNX NV €45.00 PER SHARE, NET TO THE

Exhibit (a)(1)(G) Exhibit (a)(1)(G) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares and/or ADSs (both, as defined below).

CONFIDENTIALITY AGREEMENT MADE ON JANUARY 22, 2018 BETWEEN ABLYNX, a Belgian naamloze vennootschap, having its registered offices at Technologiepark 21, 9052 Ghent, Belgium, registered with the Cross Roads Bank for Enterprises under number 0475.295.4

Exhibit (d)(2) Exhibit (d)(2) CONFIDENTIALITY AGREEMENT MADE ON JANUARY 22, 2018 BETWEEN ABLYNX, a Belgian naamloze vennootschap, having its registered offices at Technologiepark 21, 9052 Ghent, Belgium, registered with the Cross Roads Bank for Enterprises under number 0475.

U.S. Offer to Purchase For Cash ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS AND ALL SHARES REPRESENTED BY OUTSTANDING AMERICAN DEPOSITARY SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED, ABLYNX NV €45.00 PER SHARE, NET TO TH

Exhibit (a)(1)(E) Exhibit (a)(1)(E) U.S. Offer to Purchase For Cash ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS AND ALL SHARES REPRESENTED BY OUTSTANDING AMERICAN DEPOSITARY SHARES, HELD BY ALL HOLDERS, WHEREVER LOCATED, of ABLYNX NV at €45.00 PER SHARE, NET TO THE SELLER IN CASH, WITHOUT INTEREST and €45.00 PER AMERICAN DEPOSITARY SHARE, NET TO THE SELLER IN CASH, WITH

ADS Letter of Transmittal Holders of American Depositary Shares (ADSs) Evidencing Ordinary Shares, No Nominal Value, Ablynx NV Pursuant to a Tender Offer by Sanofi (“Offeror”) in connection with its Offer to Purchase all Outstanding Ordinary Shares,

Exhibit (a)(1)(C) Exhibit (a)(1)(C) ADS Letter of Transmittal To Holders of American Depositary Shares (ADSs) Evidencing Ordinary Shares, No Nominal Value, of Ablynx NV Pursuant to a Tender Offer by Sanofi (“Offeror”) in connection with its Offer to Purchase all Outstanding Ordinary Shares, No Nominal Value (“Shares”) Held by U.

SNY / Sanofi SC TO-T

SC TO-T 1 d525290dsctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Ablynx NV (Name of Subject Company (Issuer)) SANOFI (Names of Filing Persons — Offeror) Ordinary Shares, no nominal value American Depositary Shares, each of which represents one Ordi

SHARE ACCEPTANCE FORM ACCEPTANCE FORM FOR THE U.S. OFFER TO PURCHASE FOR CASH ALL OUTSTANDING ORDINARY SHARES, NO NOMINAL VALUE, HELD BY U.S. HOLDERS OF ABLYNX NV FOR €45.00 PER SHARE, NET TO THE SELLER IN CASH, WITHOUT INTEREST BY SANOFI Acceptance

Exhibit (a)(1)(B) Exhibit (a)(1)(B) SHARE ACCEPTANCE FORM ACCEPTANCE FORM FOR THE U.

TERM FACILITY AGREEMENT as Company arranged by BNP PARIBAS FORTIS SA/NV as Arranger BNP PARIBAS FORTIS SA/NV acting as Facility Agent BNP PARIBAS FORTIS SA/NV acting as Original Facility A Lender 28 January 2018 Clause Page 1. Definitions and Interpr

EX-99.B1 9 d525290dex99b1.htm EXHIBIT (B)(1) Exhibit (b)(1) Weil, Gotshal & Manges (Paris) LLP 2 rue de la Baume Paris 75008 France +33 1 44 21 97 97 main tel +33 1 42 89 57 90 main fax weil.com TERM FACILITY AGREEMENT €4,200,000,000 for SANOFI as Company arranged by BNP PARIBAS FORTIS SA/NV as Arranger with BNP PARIBAS FORTIS SA/NV acting as Facility Agent and BNP PARIBAS FORTIS SA/NV acting as O

PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018

EX-99.1 Exhibit 99.1 PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018 • Prospectus approved by the FSMA on March 27, 2018 and to be published on April 3, 2018 • Initial acceptance period will commence on April 4, 2018 and expire on May 4, 2018, subject to extension Paris, France and Ghent, Belgium – March 29, 2018 – Sanofi [Euronext: SAN; NYSE: SNY] and

ABYLY / Ablynx NV FORM 6-K (Current Report of Foreign Issuer)

Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2018 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant’s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address o

SNY / Sanofi SC TO-C

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Ablynx NV (Name of Subject Company (Issuer)) Sanofi (Name of Filing Persons (Offeror)) Ordinary Shares, no par value American Depositary Shares, each of which represents one Ordinary Share (Title of Class

Previously Announced Tender Offers By Sanofi To Acquire Ablynx Will Commence On April 4, 2018

EX-99.1 Exhibit 99.1 Previously Announced Tender Offers By Sanofi To Acquire Ablynx Will Commence On April 4, 2018 • Prospectus approved by the FSMA on March 27, 2018 and to be published on April 3, 2018 • The initial acceptance period will commence on April 4, 2018 and expire on May 4, 2018, subject to extension Paris, France and Ghent, Belgium – March 29, 2018 – Sanofi and Ablynx announced today

ABLYNX ANNOUNCES TOPLINE RESULTS FROM THE PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

EX-99.1 Exhibit 99.1 REGULATED INFORMATION – INSIDE INFORMATION ABLYNX ANNOUNCES TOPLINE RESULTS FROM THE PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS GHENT, Belgium, 26 March 2018 – Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that the Phase II dose-ranging study of vobarilizumab, the Company’s anti-IL-6R Nanobody®, did not meet the primary endpoint

ABYLY / Ablynx NV FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2018 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant’s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address of princip

ABYLY / Ablynx NV 20-F

20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-13.2 Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Ablynx NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2017 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Wim Ot

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EX-12.2 Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Wim Ottevaere, certify that: 1. I have reviewed this annual report on Form 20-F of Ablynx NV; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or

Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

EX-12.1 Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Edwin Moses, certify that: 1. I have reviewed this annual report on Form 20-F of Ablynx NV; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or om

Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-13.1 Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the annual report of Ablynx NV (the “Company”) on Form 20-F for the fiscal year ended December 31, 2017 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), I, Edwin

SCHEDULE 13D JOINT FILING AGREEMENT

EXHIBIT 2 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D (including amendments thereto) to which this joint filing agreement is attached, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.

ABYLY / Ablynx NV / VAN HERK INVESTMENTS B.V. - SC 13D/A Activist Investment

SC 13D/A 1 a18-71563sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Ablynx NV (Name of Issuer) Ordinary Shares, no par value, and American Depositary Shares, each of which represents one Ordinary Share (Title of Class of Securities) BE0003877942 (Ordinary Shares) 00372Y105 (Americ

POWER OF ATTORNEY

EXHIBIT 3 POWER OF ATTORNEY Each of the undersigned, (i) Van Herk Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHI”), (ii) Van Herk Private Equity Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHPI”), (iii) Stichting Administratiekantoor Penulata, a foundation organized unde

PRESS RELEASE

EXHIBIT 1 PRESS RELEASE Van Herk Investments willing to consider offer that properly reflects the value of Ablynx ROTTERDAM, The Netherlands, 18 January 2018 - Van Herk Investments B.

PRESS RELEASE

EXHIBIT 1 PRESS RELEASE Van Herk Investments willing to consider offer that properly reflects the value of Ablynx ROTTERDAM, The Netherlands, 18 January 2018 - Van Herk Investments B.

ABYLY / Ablynx NV / VAN HERK INVESTMENTS B.V. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Ablynx NV (Name of Issuer) Ordinary Shares, no par value, and American Depositary Shares, each of which represents one Ordinary Share (Title of Class of Securities) BE0003877942 (Ordinary Shares) 00372Y105 (American Depositary Shares) (CUSIP Number) Mar

POWER OF ATTORNEY

EXHIBIT 3 POWER OF ATTORNEY Each of the undersigned, (i) Van Herk Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHI”), (ii) Van Herk Private Equity Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (“VHPI”), (iii) Stichting Administratiekantoor Penulata, a foundation organized unde

SCHEDULE 13D JOINT FILING AGREEMENT

EXHIBIT 2 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D (including amendments thereto) to which this joint filing agreement is attached, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.

ABYLY / Ablynx NV 6-K (Current Report of Foreign Issuer)

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2018 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant’s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address of pri

ABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTION

EX-99.1 Exhibit 99.1 ABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTION GHENT, Belgium, 2 March 2018—Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that the first patient has been dosed in the Japanese Phase II study of ALX-0171, the Company’s wholly-owned inhaled Nanobody® to treat respiratory syncytial virus (RSV) infectio

Sanofi Announces Receipt of Antitrust Clearances in

EX-99.1 2 d545812dex991.htm EX-99.1 Exhibit 99.1 Sanofi Announces Receipt of Antitrust Clearances in Connection with the Acquisition of Ablynx Paris (France) – March 1, 2018 – Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) has expired and that Sanofi has received clearance from the Federal Cartel Office of Germany (the

SNY / Sanofi SC TO-C

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Ablynx NV (Name of Subject Company (Issuer)) Sanofi (Name of Filing Persons (Offeror)) Ordinary Shares, no par value American Depositary Shares, each of which represents one Ordinary Share (Title of Class

SCHEDULE 13D JOINT FILING AGREEMENT

EXHIBIT 2 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D (including amendments thereto) to which this joint filing agreement is attached, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.

ABYLY / Ablynx NV / VAN HERK INVESTMENTS B.V. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Ablynx NV (Name of Issuer) Ordinary Shares, no par value, and American Depositary Shares, each of which represents one Ordinary Share (Title of Class of Securities) BE0003877942 (Ordinary Shares) 00372Y105 (American Depositary Shares) (CUSIP Number) Feb

PRESS RELEASE

EXHIBIT 1 PRESS RELEASE Van Herk Investments willing to consider offer that properly reflects the value of Ablynx ROTTERDAM, The Netherlands, 18 January 2018 - Van Herk Investments B.

SNY / Sanofi SC TO-C

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Ablynx NV (Name of Subject Company (Issuer)) Sanofi (Name of Filing Persons (Offeror)) Ordinary Shares, no par value American Depositary Shares, each of which represents one Ordinary Share (Title of Class

2

EX-99.1 Exhibit 99.1 Paris, February 14th, 2018 Dear Ablynx Employees, On January 22nd, Ablynx and Sanofi announced an agreement to join forces and help make a meaningful impact on patients worldwide. As the Chief Executive Officer of Sanofi, I?d like to introduce myself and share a little about the company. Sanofi is a global company devoted to human health care with a direct presence in more tha

ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES

EX-99.2 Exhibit 99.2 REGULATED INFORMATION ? INSIDE INFORMATION ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES GHENT, Belgium, 16 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Sanofi has exercised its option to license two additional target combinations as part of the research collaboration signed in July

ABYLY / Ablynx NV 6-K (Current Report of Foreign Issuer)

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2018 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address of

ABLYNX ANNOUNCES BOARD CHANGES

EX-99.1 2 d524974dex991.htm EX-99.1 Exhibit 99.1 ABLYNX ANNOUNCES BOARD CHANGES GHENT, Belgium, 7 February 2018 – Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that Dr Bo Jesper Hansen, acting as permanent representative of Orfacare Consulting GmbH, has decided to resign from the Board of Directors with immediate effect for personal reasons. Having contributed to Ablynx’s recent M

ABYLY / Ablynx NV / Baker Brothers Advisors LP - SCHEDULE 13G Passive Investment

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

AGREEMENT

EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Ablynx NV is being filed with the Securities and Exchange Commission on behalf of each of them. February 13, 2018 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its general part

- END -

EX-99.1 Exhibit 99.1 Full Regular Transcription Sanofi Investor Relations Monday, January 29th, 2018 at 2:30 pm CET Duration: 51 minutes COMPANY REPRESENTATIVES Olivier Brandicourt ? Chief Executive Officer Elias Zerhouni?President, Global R&D Bill Sibold?Vice President, Sanofi Genzyme J?r?me Contamine ? Executive Vice President, Chief Financial Officer George Grofik?Vice President, Head of Invest

SNY / Sanofi SC TO-C

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Ablynx NV (Name of Subject Company (Issuer)) Sanofi (Name of Filing Persons (Offeror)) Ordinary Shares, no par value American Depositary Shares, each of which represents one Ordinary Share (Title of Class

Social Media Posts

EX-99.3 Exhibit 99.3 Social Media Posts 29 January 2018 Twitter:

Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding

EX-99.2 Sanofi to Acquire Ablynx Advancing Research Platforms and Building a Leading Rare Blood Disorders Franchise January 29, 2018 Exhibit 99.2 Forward Looking Statements This presentation contains forward-looking statements. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding pla

Sanofi to acquire Ablynx for €3.9 Billion

EX-99.1 Exhibit 99.1 Sanofi to acquire Ablynx for ?3.9 Billion ? Strengthens Sanofi?s R&D strategy with innovative Nanobody? technology platform ? Expands growing rare blood disorders franchise with Ablynx?s late-stage investigational caplacizumab aTTP treatment ? Unanimously approved by Sanofi and Ablynx Boards of Directors Paris, France and Ghent, Belgium ? January 29, 2018 ? Sanofi and Ablynx,

SNY / Sanofi SC TO-C

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Ablynx NV (Name of Subject Company (Issuer)) Sanofi (Name of Filing Persons (Offeror)) Ordinary Shares, no par value American Depositary Shares, each of which represents one Ordinary Share (Title of Class

ABYLY / Ablynx NV SC 14D9C

SC 14D9C SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Ablynx NV (Name of Subject Company) Ablynx NV (Name of Person(s) Filing Statement) Ordinary shares, no nominal value (?Shares?) American Depositary Shares (?ADSs?), each representing one Share (Title of

NOTICE PUBLISHED BY THE FINANCIAL SERVICES AND MARKETS AUTHORITY PURSUANT TO ARTICLE 7 OF THE ROYAL DECREE OF 27 APRIL 2007 ON TAKEOVER OFFERS

EX-99.2 Exhibit 99.2 29 January 2018 - 8am NOTICE PUBLISHED BY THE FINANCIAL SERVICES AND MARKETS AUTHORITY PURSUANT TO ARTICLE 7 OF THE ROYAL DECREE OF 27 APRIL 2007 ON TAKEOVER OFFERS The Financial Services and Markets Authority (?FSMA?), pursuant to Article 7 of the Royal Decree of 27 April 2007 on takeover offers (the ?Takeover Decree?), hereby publishes the notice it received on 29 January 20

SANOFI TO ACQUIRE ABLYNX FOR €3.9 BILLION

EX-99.1 Exhibit 99.1 Regulated information ? inside information SANOFI TO ACQUIRE ABLYNX FOR ?3.9 BILLION ? Strengthens Sanofi?s R&D strategy with innovative Nanobody? technology platform ? Expands growing rare blood disorders franchise with Ablynx?s late-stage investigational caplacizumab aTTP treatment ? Unanimously approved by Sanofi and Ablynx Boards of Directors PARIS, France and GHENT, Belgi

ABYLY / Ablynx NV 6-K (Current Report of Foreign Issuer)

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2018 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address of p

PRESS RELEASE

EXHIBIT 1 PRESS RELEASE Van Herk Investments willing to consider offer that properly reflects the value of Ablynx ROTTERDAM, The Netherlands, 18 January 2018 - Van Herk Investments B.

ABYLY / Ablynx NV / VAN HERK INVESTMENTS B.V. - SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Ablynx NV (Name of Issuer) Ordinary Shares, no par value, and American Depositary Shares, each of which represents one Ordinary Share (Title of Class of Securities) BE0003877942 (Ordinary Shares) 00372Y105 (American Depositary Shares) (CUSIP Number) Januar

SCHEDULE 13D JOINT FILING AGREEMENT

EXHIBIT 2 SCHEDULE 13D JOINT FILING AGREEMENT In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D (including amendments thereto) to which this joint filing agreement is attached, and further agree that this Joint Filing Agreement be included as an exhibit to such joint filing.

ABYLY / Ablynx NV 6-K (Current Report of Foreign Issuer)

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2018 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address of p

ABLYNX ANNOUNCES BOARD CHANGES

EX-99.1 Exhibit 99.1 8 January 2018 ? 5:30 pm CET ABLYNX ANNOUNCES BOARD CHANGES GHENT, Belgium, 8 January 2018 (5:30 pm CET) ? Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that Dr Peter Fellner, who has served as Chairman since 20131, has decided to resign from the Board with immediate effect for personal reasons. He will be succeeded by Dr Bo Jesper Hansen, acting as permanent

ABYLY / Ablynx NV 6-K (Current Report of Foreign Issuer)

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2017 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address of

ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB

EX-99.1 Exhibit 99.1 ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB ? Comparable pharmacokinetics (PK) observed in Japanese and Caucasian healthy volunteers ? Caplacizumab was well-tolerated in all groups GHENT, Belgium, 21 December 2017 ? Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that the single and multiple dose Phase I study demonstrat

ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP

EX-99.1 Exhibit 99.1 ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP Additional results from the Phase III HERCULES study showed that treatment with caplacizumab resulted in: ? 38% relative reduction in the number of days of plasma exchange (PEX) ? 41% relative reduction in the volume of plasma used ? 65% relative reduction

ABYLY / Ablynx NV FORM 6-K (Current Report of Foreign Issuer)

Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2017 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Addres

ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION

EX-99.1 Exhibit 99.1 ABLYNX WILL HOST A WEBCAST TO DISCUSS ADDITIONAL DATA FROM ITS PHASE III HERCULES STUDY OF CAPLACIZUMAB IN ACQUIRED TTP FOLLOWING ASH LATE-BREAKING DATA PRESENTATION GHENT, Belgium, 7 December 2017 ? Ablynx NV [Euronext Brussels and Nasdaq: ABLX] announced today that the Ablynx management team will host a conference call and webcast to present additional data from the Phase II

ABYLY / Ablynx NV 6-K (Current Report of Foreign Issuer)

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2017 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address of

ABYLY / Ablynx NV / VAN HERK INVESTMENTS B.V. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ablynx N.V. (Name of Issuer) Ordinary Shares, no par value per share (Title of Class of Securities) 00372Y105 (CUSIP Number) October 27, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that they are filing a statement on Schedule 13G jointly pursuant to Rule 13d-1(k)(1). Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completene

ABLYF / Ablynx NV FORM 6-K (Current Report of Foreign Issuer)

Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2017 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Addres

RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP SELECTED FOR PRESENTATION IN THE LATE-BREAKING ABSTRACTS SESSION AT THE 2017 ASH ANNUAL MEETING

Exhibit 99.1 Exhibit 99.1 RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP SELECTED FOR PRESENTATION IN THE LATE-BREAKING ABSTRACTS SESSION AT THE 2017 ASH ANNUAL MEETING GHENT, Belgium, 21 November 2017 (3.15pm CET) ? Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced that results from its Phase III HERCULES study of caplacizumab have been se

ABLYF / Ablynx NV 6-K (Current Report of Foreign Issuer)

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2017 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address of

ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE Positive Phase III results with caplacizumab and a successful U.S. IPO

EX-99.1 Exhibit 99.1 REGULATED INFORMATION ABLYNX ANNOUNCES RESULTS FOR THE FIRST NINE MONTHS OF 2017 AND A YEAR-TO-DATE BUSINESS UPDATE Positive Phase III results with caplacizumab and a successful U.S. IPO GHENT, Belgium, 16 November 2017 ? Ablynx NV [Euronext Brussels and Nasdaq: ABLX] today announced its non-audited financial results for the first nine months of 2017, a business update for the

Ablynx FORM 6-K (Current Report of Foreign Issuer)

Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2017 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address

ABLYNX CLOSES ON UNDERWRITERS’ OPTION TO PURCHASE $30 MILLION OF ADDITIONAL SHARES IN THE U.S. INITIAL PUBLIC OFFERING

EX-99.1 Exhibit 99.1 REGULATED INFORMATION ABLYNX CLOSES ON UNDERWRITERS? OPTION TO PURCHASE $30 MILLION OF ADDITIONAL SHARES IN THE U.S. INITIAL PUBLIC OFFERING GHENT, Belgium, 30 October 2017?Ablynx NV [Euronext Brussels and Nasdaq: ABLX], a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody? platform to develop treatments for a broad range of therapeutic indication

ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD

EX-99.1 Exhibit 99.1 REGULATED INFORMATION ? INSIDE INFORMATION ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS? OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX], a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody? platform to develop treatments for a broad range of t

Ablynx FORM 6-K (Current Report of Foreign Issuer)

Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2017 Commission File Number: 001-38259 ABLYNX NV (Translation of registrant?s name into English) Technologiepark 21 9052 Ghent/Zwijnaarde, Belgium Tel: +32 9 262 00 00 (Address

ABLYNX CLOSES $200 MILLION INITIAL PUBLIC OFFERING IN THE UNITED STATES

EX-99.2 Exhibit 99.2 REGULATED INFORMATION ABLYNX CLOSES $200 MILLION INITIAL PUBLIC OFFERING IN THE UNITED STATES GHENT, Belgium, 27 October 2017 - Ablynx NV [Euronext Brussels and Nasdaq: ABLX], a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody? platform to develop treatments for a broad range of therapeutic indications with an unmet medical need, announced today

11,430,000 Ordinary Shares (In the Form of American Depositary Shares) $17.50 per American Depositary Share

424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration Nos. 333-220763 and 333-221097 11,430,000 Ordinary Shares (In the Form of American Depositary Shares) $17.50 per American Depositary Share This is Ablynx NV?s initial public offering in the United States. We are offering an aggregate of 11,430,000 of our ordinary shares in the form of American Depositary Shares, or ADSs, to inve

Ablynx F-1MEF

F-1MEF As filed with the United States Securities and Exchange Commission on October 25, 2017.

Ablynx 8-A12B

8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ABLYNX NV (Exact Name of Registrant as Specified in its Charter) Belgium Not Applicable (State or other jurisdiction of incorporation or organization) (I.

As filed with the United States Securities and Exchange Commission on October 24, 2017

F-1/A Table of Contents As filed with the United States Securities and Exchange Commission on October 24, 2017 Registration No.

Research Collaboration and Exclusive License Agreement, dated January 31, 2014, by and between Ablynx NV and Merck Sharp & Dohme Corp.

EX-10.4 Exhibit 10.4 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT

Ablynx F-1/A

F-1/A As filed with the United States Securities and Exchange Commission on October 20, 2017 Registration No.

License Agreement, dated May 20, 2010, by and between Ablynx NV and Research Corporation Technologies, Inc.

Exhibit 10.6 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. LICENSE AGREEMENT Effective May 20th, 2010 (the ?Effective Dat

Amendment, dated February 27, 2015 to the License Agreement, dated May 20, 2010, by and between Ablynx NV and Research Corporation Technologies, Inc.

Exhibit 10.7 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CONFIDENTIAL AMENDMENT This amendment (”Amendment”), made on F

ABYLY / Ablynx NV ESP

VIA EDGAR AND FACSIMILE October 20, 2017 United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4546 100 F Street, N.

ABYLY / Ablynx NV ESP

Underwriters Acceleration Req. MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED One Bryant Park New York, New York 10036 J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, New York 10179 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 October 20, 2017 Re: ABLYNX NV (the ?Registrant?) Registration Statement on Form F-1 (File No. 333-220763) Request for Acceleration of Effective Dat

As filed with the United States Securities and Exchange Commission on October 20, 2017

F-1/A Table of Contents As filed with the United States Securities and Exchange Commission on October 20, 2017 Registration No.

ABYLY / Ablynx NV ESP

SEC Response Letter Mitchell S. Bloom +1 617 570 1055 [email protected] Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 October 20, 2017 VIA EDGAR AND OVERNIGHT MAIL U.S. Securities and Exchange Commission Division of Corporation Finance - Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-3010 Attention: Irene Paik and Joseph McC

RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. ABLYNX N.V.

Exhibit 10.4 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and

RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. ABLYNX N.V.

Exhibit 10.4 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and

As filed with the United States Securities and Exchange Commission on October 17, 2017

F-1/A Table of Contents As filed with the United States Securities and Exchange Commission on October 17, 2017 Registration No.

Amendment, dated July 20, 2015, to the Research Collaboration and Exclusive License Agreement, dated January 31, 2014, by and between Ablynx NV and Merck Sharp & Dohme Corp

EX-10.5 Exhibit 10.5 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CONFIDENTIAL AMENDMENT This amendment (”Amendment”), e

Form of Underwriting Agreement

Exhibit 1.1 ABLYNX NV (a public limited liability company (?naamloze vennootschap?) organized and existing under the laws of the Kingdom of Belgium) Ordinary Shares and American Depositary Shares UNDERWRITING AGREEMENT Dated: October [?], 2017 ABLYNX NV (a public limited liability company (?naamloze vennootschap?) organized and existing under the laws of the Kingdom of Belgium) Ordinary shares, wi

Collaboration and License Agreement, dated July 19, 2017, by and between Ablynx NV and Sanofi

Exhibit 10.8 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. COLLABORATION AND LICENSE AGREEMENT between ABLYNX N.V. and SA

APPENDIX: RANK-L LICENSE AGREEMENT LICENSE AGREEMENT

Exhibit 10.7 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CONFIDENTIAL AMENDMENT This amendment (?Amendment?), made on F

LICENSE AGREEMENT

Exhibit 10.6 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. LICENSE AGREEMENT Effective May 20th, 2010 (the ?Effective Dat

As filed with the United States Securities and Exchange Commission on October 12, 2017

F-1/A Table of Contents As filed with the United States Securities and Exchange Commission on October 12, 2017 Registration No.

RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. ABLYNX N.V.

EX-10.4 Exhibit 10.4 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT

W I T N E S S E T H:

J.P.Morgan J.P.Morgan AMENDMENT NO. 1, dated as of , 2017 (the "Amendment"), to the Deposit Agreement dated as of September 5, 2014 (the "Deposit Agreement"), among Ablynx NV, incorporated under the laws of Belgium (the "Company"), JPMorgan Chase Bank, N.A., as depositary (the "Depositary"), and all holders from time to time of American depositary receipts ("ADRs") issued thereunder. W I T N E S S

As filed with the U.S. Securities and Exchange Commission on October 4, 2017

As filed with the U.S. Securities and Exchange Commission on October 4, 2017 Registration No. 333-198467 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts Ablynx NV (Exact name of issuer of deposited securities as specified in it

Certification under Rule 466

Certification under Rule 466 The depositary, JPMorgan Chase Bank, N.A., represents and certifies the following: (1) That it previously had filed a registration statement on Form F-6 (Ablynx NV, 333-198467) that the Commission declared effective, with terms of deposit identical to the terms of deposit of this registration statement. (2) That its ability to designate the date and time of effectivene

Terms and Conditions of 3.25% senior unsecured convertible bonds due May 2020

EX-4.4 Exhibit 4.4 TERMS AND CONDITIONS OF THE BONDS The following is the text of the Terms and Conditions of the Bonds. The issue of the €100,000,000 3.25 per cent. Convertible Bonds due 27 May 2020 (the “Bonds”, which expression shall, unless otherwise indicated, include any Further Bonds) was (save in respect of any such Further Bonds) authorised by a resolution of the Board of Directors of Abl

Form of American Depositary Receipt (included in Exhibit 4.2)

Exhibit 4.2 AMENDMENT NO. 1 TO DEPOSIT AGREEMENT BETWEEN ABLYNX NV, JPMORGAN CHASE BANK, N.A. AS DEPOSITARY AND HOLDERS OF AMERICAN DEPOSITARY RECEIPTS WORLDWIDE SECURITIES SERVICES jpmorgan.com AMENDMENT NO. 1, dated as of , 2017 (the ?Amendment?), to the Deposit Agreement dated as of September 5, 2014 (the ?Deposit Agreement?), among Ablynx NV, incorporated under the laws of Belgium (the ?Compan

Articles of Association (English translation)

Exhibit 3.1 UNOFFICIAL TRANSLATION OF THE ORIGINAL DUTCH ARTICLES OF ASSOCIATION FOR INFORMATION PURPOSES ONLY ABLYNX Public limited liability company making or having made a public call on savings (?naamloze vennootschap die een openbaar beroep op het spaarwezen doet of heeft gedaan?) Technologiepark 21 B-9052 Zwijnaarde Belgium Enterprise Number 0475.295.446 Register of Legal Entities Ghent ARTI

Warrant Plans (English translation)

Exhibit 10.2 Unofficial translation of Dutch original In the event of any discrepancy between the English translation and the original Dutch version, the latter shall prevail. ABLYNX NV Limited Liability Company (?Naamloze Vennootschap?) Registered offices: Technologiepark 4, 9052 Zwijnaarde Company number: 0475.295.446 (the ?Company?) SPECIAL REPORT BY THE BOARD OF DIRECTORS IN ACCORDANCE WITH AR

Exclusive License Agreement, dated September 20, 2013, by and between Ablynx NV and AbbVie SARL

Exhibit 10.3 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Confidential EXCLUSIVE LICENSE AGREEMENT between ABLYNX NV and

Lease Agreement, dated December 15, 2016, by and between Ablynx NV and Bio-Versneller NV (English translation)

EX-10.1 5 d407559dex101.htm EX-10.1 Exhibit 10.1 SERVICE AGREEMENT REGARDING BUSINESS-SUPPORT CENTRE “BIO-ACCELERATOR” Between: 1. BIO-VERSNELLER NV, with its registered office at the following address: Karel Oomsstraat 37, 2018 Antwerp with business registration number 0807.734.044, duly represented by AOB Consulting BVBA, a director, permanently represented by Mr Alain Ooms and Mr Thierry Storme

Power of Attorney

Form F-1 Table of Contents As filed with the United States Securities and Exchange Commission on October 2, 2017 Registration No.

Ablynx A

Table of Contents As confidentially submitted with the United States Securities and Exchange Commission on September 25, 2017 as Amendment No.

ABYLY / Ablynx NV TR

DRSLTR Mitchell S. Bloom +1 617 570 1055 [email protected] Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 September 25, 2017 VIA EDGAR AND OVERNIGHT MAIL U.S. Securities and Exchange Commission Division of Corporation Finance?Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-3010 Attention: Irene Paik and Joseph McCann Re: Ablyn

Ablynx A

DRS/A As confidentially submitted with the United States Securities and Exchange Commission on September 13, 2017 as Amendment No.

Milestone Payment

EX-10.5 Exhibit 10.5 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CONFIDENTIAL AMENDMENT This amendment (?Amendment?), e

EXCLUSIVE LICENSE AGREEMENT ABLYNX NV ABBVIE S.À.R.L. Dated as of September 20, 2013

EX-10.3 Exhibit 10.3 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Confidential EXCLUSIVE LICENSE AGREEMENT between ABLYN

COLLABORATION AND LICENSE AGREEMENT ABLYNX N.V.

EX-10.8 Exhibit 10.8 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. COLLABORATION AND LICENSE AGREEMENT between ABLYNX N.V

APPENDIX: RANK-L LICENSE AGREEMENT LICENSE AGREEMENT

Exhibit 10.7 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CONFIDENTIAL AMENDMENT This amendment (?Amendment?), made on F

RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT by and between MERCK SHARP & DOHME CORP. ABLYNX N.V.

EX-10.4 Exhibit 10.4 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[...***...]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT

LICENSE AGREEMENT

Exhibit 10.6 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. LICENSE AGREEMENT Effective May 20th, 2010 (the ?Effective Dat

As confidentially submitted with the United States Securities and Exchange Commission on August 30, 2017 as Amendment No. 4 to the Confidential Submission. This draft registration statement has not been publicly filed with the United States Securitie

DRS/A #4 As confidentially submitted with the United States Securities and Exchange Commission on August 30, 2017 as Amendment No.

Ablynx A

DRS/A Table of Contents As confidentially submitted with the United States Securities and Exchange Commission on August 28, 2017 as Amendment No.

ABYLY / Ablynx NV TR

DRSLTR Mitchell S. Bloom +1 617 570 1055 [email protected] Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 August 28, 2017 VIA EDGAR AND OVERNIGHT MAIL U.S. Securities and Exchange Commission Division of Corporation Finance - Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-3010 Attention: Irene Paik and Joseph McCann Re: Ablynx

Ablynx A

DRS/A As confidentially submitted with the United States Securities and Exchange Commission on August 10, 2017 as Amendment No.

EXCLUSIVE LICENSE AGREEMENT ABLYNX NV ABBVIE S.À.R.L. Dated as of September 20, 2013

EX-10.4 CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH ?[...***...]?. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Exhibit 10.4 Confidential EXECUTION VERSION EXCLUSIVE LICENSE AGREE

As confidentially submitted with the United States Securities and Exchange Commission on July 26, 2017 as Amendment No. 1 to the Confidential Submission. This draft registration statement has not been publicly filed with the United States Securities

DRS/A Table of Contents As confidentially submitted with the United States Securities and Exchange Commission on July 26, 2017 as Amendment No.

ABYLY / Ablynx NV TR

DRSLTR Mitchell S. Bloom +1 617 570 1055 [email protected] Goodwin Procter LLP 100 Northern Avenue Boston, MA 02210 goodwinlaw.com +1 617 570 1000 July 26, 2017 VIA EDGAR AND OVERNIGHT MAIL U.S. Securities and Exchange Commission Division of Corporation Finance - Office of Healthcare & Insurance 100 F Street, N.E. Washington, D.C. 20549-3010 Attention: Irene Paik and Joseph McCann Re: Ablynx N

Consent of Director Nominee

EX-99.1 Exhibit 99.1 Consent of Director Nominee Pursuant to Rule 438 promulgated under the Securities Act of 1933, as amended, in connection with the Registration Statement on Form F-1 (the “Registration Statement”) of Ablynx NV (the “Company”), the undersigned hereby consents to being named and described as a person who will become a director of the Company in the Registration Statement and any

Ablynx

DRS F-1 Table of Contents As confidentially submitted with the United States Securities and Exchange Commission on June 16, 2017.

DMLRY / Daimler AG F-6 - -

As filed with the U.S. Securities and Exchange Commission on August 29, 2014 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-6 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 For Depositary Shares Evidenced by American Depositary Receipts Ablynx NV (Exact name of issuer of deposited securities as specified in its charter) n/a (Translation of issuer's

Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 August 27, 2014

Ziegler, Ziegler & Associates LLP Counselors at Law 570 Lexington Avenue, 44th Floor New York, New York 10022 (212) 319-7600 Telecopier (212) 319-7605 August 27, 2014 JPMorgan Chase Bank, N.

TABLE OF CONTENTS

J.P.Morgan J.P.Morgan TABLE OF CONTENTS Page PARTIES 1 RECITALS 1 Section 1. Certain Definitions (a) ADR Register 1 (b) ADRs; Direct Registration ADRs 1 (c) ADS 1 (d) Custodian 1 (e) Deliver, execute, issue et al. 1 (f) Delivery Order 1 (g) Deposited Securities 2 (h) Direct Registration System 2 (i) Holder 2 (j) Securities Act of 1933 2 (k) Securities Exchange Act of 1934 2 (l) Shares 2 (m) Transf